CLIMB BIO INC (CLYM) Stock Price & Overview
NASDAQ:CLYM • US28658R1068
Current stock price
The current stock price of CLYM is 9.14 USD. Today CLYM is up by 1.33%. In the past month the price increased by 28.55%. In the past year, price increased by 619.69%.
CLYM Key Statistics
- Market Cap
- 436.618M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.89
- Dividend Yield
- N/A
CLYM Stock Performance
CLYM Stock Chart
CLYM Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CLYM. When comparing the yearly performance of all stocks, CLYM is one of the better performing stocks in the market, outperforming 99.32% of all stocks.
CLYM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CLYM. CLYM has a great financial health rating, but its profitability evaluates not so good.
CLYM Earnings
CLYM Forecast & Estimates
18 analysts have analysed CLYM and the average price target is 15.67 USD. This implies a price increase of 71.45% is expected in the next year compared to the current price of 9.14.
CLYM Groups
Sector & Classification
CLYM Financial Highlights
Over the last trailing twelve months CLYM reported a non-GAAP Earnings per Share(EPS) of -0.89. The EPS increased by 58.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.68% | ||
| ROE | -37.3% | ||
| Debt/Equity | 0 |
CLYM Ownership
CLYM Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.4 | 355.432B | ||
| AMGN | AMGEN INC | 15.09 | 188.147B | ||
| GILD | GILEAD SCIENCES INC | 14.75 | 165.877B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.09 | 110.672B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.03 | 80.984B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.76 | 41.869B | ||
| INSM | INSMED INC | N/A | 31.046B | ||
| NTRA | NATERA INC | N/A | 28.508B | ||
| BIIB | BIOGEN INC | 11.44 | 27.573B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 26.65B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.41 | 25.108B | ||
| MRNA | MODERNA INC | N/A | 20.96B | ||
| INCY | INCYTE CORP | 12.23 | 19B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CLYM
Company Profile
Climb Bio, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Wellesley Hills, Massachusetts and currently employs 28 full-time employees. The company went IPO on 2021-08-10. The firm is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The firm is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).
Company Info
IPO: 2021-08-10
CLIMB BIO INC
20 William Street, Suite 145
Wellesley Hills MASSACHUSETTS US
Employees: 29
Phone: 18668572596
CLIMB BIO INC / CLYM FAQ
What does CLYM do?
Climb Bio, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Wellesley Hills, Massachusetts and currently employs 28 full-time employees. The company went IPO on 2021-08-10. The firm is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The firm is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).
What is the stock price of CLIMB BIO INC today?
The current stock price of CLYM is 9.14 USD. The price increased by 1.33% in the last trading session.
What is the dividend status of CLIMB BIO INC?
CLYM does not pay a dividend.
What is the ChartMill rating of CLIMB BIO INC stock?
CLYM has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of CLIMB BIO INC (CLYM)?
CLIMB BIO INC (CLYM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.89).
Can you provide the ownership details for CLYM stock?
You can find the ownership structure of CLIMB BIO INC (CLYM) on the Ownership tab.